SEC Form 4 · accession 0001615774-18-001627
CALMARE THERAPEUTICS Inc · CTTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Philip Richtarich
Officer — Chief Financial Officer
Period of report
Feb 12, 2018
Accepted (ET)
Mar 6, 2018 · 1:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000102198
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 12, 2018 | A | 333,333 | $0.09 | A | 333,333 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1A bonus of $30,000 to be paid in Common Stock was granted on 5/1/2017. The closing stock price on 5/1/2017 was $0.09